Actiq (brand only) — United Healthcare

Preferred products

• fentanyl citrate lozenges (generic Actiq)
• Lazanda

Initial criteria

• Submission of medical records demonstrating ALL of the following:
• Use is for management of breakthrough pain associated with a cancer diagnosis (cancer diagnosis must be documented in the medical records) AND
• Patient must have at least a one week history of one of the following medications to demonstrate tolerance to opioids: oral morphine sulfate ≥ 60 mg/day, fentanyl transdermal patch ≥ 25 mcg/hr, oral oxycodone ≥ 30 mg/day, oral hydromorphone ≥ 8 mg/day, oral oxymorphone ≥ 25 mg/day, oral hydrocodone ≥ 60 mg/day, or an equianalgesic opioid dose (e.g., oral methadone ≥ 20 mg/day) AND
• Patient is currently taking a long-acting opioid around the clock for cancer pain AND
• Patient has a history of failure, contraindication, or intolerance to fentanyl citrate lozenges (generic Actiq) AND
• Patient has a history of failure, contraindication, or intolerance to Lazanda AND
• ONE of the following: (1) patient is not concurrently receiving an alternative transmucosal fentanyl product OR (2) the prescriber is requesting termination of all current authorizations for alternative transmucosal fentanyl products to begin treatment with the requested medication. Only one transmucosal fentanyl product will be approved at a time; if previous authorizations cannot be terminated, the PA request will be denied.
• OR patient is currently taking Actiq (brand only) or Fentora and does not meet the medical necessity criteria based on FDA-approved indication; a one-time fill may be approved for transition to an alternative treatment.

Approval duration

12 months